Radiolanthanum: Promising theranostic radionuclides for PET, alpha, and Auger-Meitner therapy

Velikyan, 2012, Molecular imaging and radiotherapy: theranostics for personalized patient management, Theranostics, 2, 424, 10.7150/thno.4428 Poty, 2018, α-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1, J Nucl Med, 59, 878, 10.2967/jnumed.116.186338 Nelson, 2020, Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications, Pharmaceutics, 13, 49, 10.3390/pharmaceutics13010049 Ku, 2019, Auger electrons for cancer therapy - a review, EJNMMI Radiopharm Chem, 4, 27, 10.1186/s41181-019-0075-2 Filosofov, 2021, Potent candidates for targeted auger therapy: production and radiochemical considerations, Nucl Med Biol, 94–95, 1, 10.1016/j.nucmedbio.2020.12.001 Kassis, 2011, Molecular and cellular radiobiological effects of auger emitting radionuclides, Radiat Prot Dosimetry, 143, 241, 10.1093/rpd/ncq385 Pirovano, 2021, Auger: the future of precision medicine, Nucl Med Biol, 96–97, 50, 10.1016/j.nucmedbio.2021.03.002 Scheinberg, 2011, Actinium-225 in targeted alpha-particle therapeutic applications, Curr Radiopharm, 4, 306, 10.2174/1874471011104040306 Kratochwil, 2016, 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer, J Nucl Med, 57, 1941, 10.2967/jnumed.116.178673 Zacherl, 2021, First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients, J Nucl Med, 62, 669, 10.2967/jnumed.120.251017 Morgenstern, 2018, An overview of targeted alpha therapy with 225Actinium and 213Bismuth, Curr Radiopharm, 11, 200, 10.2174/1874471011666180502104524 Sathekge, 2019, 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study, Eur J Nucl Med Mol Imaging, 46, 129, 10.1007/s00259-018-4167-0 Rathke, 2021, First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT, Eur J Nucl Med Mol Imaging, 48, 311, 10.1007/s00259-020-04875-y Aluicio-Sarduy, 2019, Production and in vivo PET/CT imaging of the theranostic pair 132/135La, Sci Rep, 9, 10658, 10.1038/s41598-019-47137-0 Aluicio-Sarduy, 2021, Cyclotron-produced 132La as a PET imaging surrogate for therapeutic 225Ac, J Nucl Med, 62, 1012, 10.2967/jnumed.120.255794 Aluicio-Sarduy, 2020, Establishing radiolanthanum chemistry for targeted nuclear medicine applications, Chemistry, 26, 1238, 10.1002/chem.201905202 Nelson, 2020, High yield cyclotron production of a novel 133/135La theranostic pair for nuclear medicine, Sci Rep, 10, 22203, 10.1038/s41598-020-79198-x Nelson, 2022, First in vivo and phantom imaging of cyclotron-produced 133La as a theranostic radionuclide for 225Ac and 135La, J Nucl Med, 63, 584, 10.2967/jnumed.121.262459 Bailey, 2021, Developing the 134Ce and 134La pair as companion positron emission tomography diagnostic isotopes for 225Ac and 227Th radiotherapeutics, Nat Chem, 13, 284, 10.1038/s41557-020-00598-7 Abel, 2018, Half-lives of 132La and 135La, Phys Rev., 97 Fonslet, 2017, 135La as an Auger-electron emitter for targeted internal radiotherapy, Phys Med Biol, 63, 10.1088/1361-6560/aa9b44 Tárkányi, 2010, Study of activation cross sections of proton induced reactions on barium: production of 131Ba–>131Cs, Appl Radiat Isot, 68, 1869, 10.1016/j.apradiso.2010.03.010 Thiele, 2017, An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy, Angew Chem Int Ed Engl, 56, 14712, 10.1002/anie.201709532 Yang, 2020, Synthesis and evaluation of a macrocyclic actinium-225 chelator, quality control and in vivo evaluation of 225 Ac-crown-αMSH peptide, Chemistry, 26, 11435, 10.1002/chem.202002999 Levin, 1999, Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution, Phys Med Biol, 44, 781, 10.1088/0031-9155/44/3/019 Pourmand, 2010, Distribution coefficients of 60 elements on TODGA resin: application to Ca, Lu, Hf,U and Th isotope geochemistry, Talanta, 81, 741, 10.1016/j.talanta.2010.01.008 Chakravarty, 2022, Electrochemical separation of 132/135La theranostic pair from proton irradiated Ba target, Sep Purif Technol, 280, 10.1016/j.seppur.2021.119908 D'Haese, 2019, Human health risk associated with the management of phosphorus in freshwaters using lanthanum and aluminium, Chemosphere, 220, 286, 10.1016/j.chemosphere.2018.12.093 Laszlo, 1952, Biological studies on stable and radio-active rare earth compounds. I. On the distribution of lanthanum in the mammalian organism, J Natl Cancer Inst, 13, 559 Thiele, 2018, Actinium-225 for targeted α therapy: coordination chemistry and current chelation approaches, Cancer Biother Radiopharm, 33, 336 Rochman, 2016, The TENDL library: hope, reality and future, 146 Ferguson, 2019, Comparison of scandium-44g with other PET radionuclides in pre-clinical PET phantom imaging, EJNMMI Phys, 6, 23, 10.1186/s40658-019-0260-0 Newton, 2001, Long-term retention of injected barium-133 in man, Radiat Prot Dosimetry, 97, 231, 10.1093/oxfordjournals.rpd.a006668 Lubberink, 2002, Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy, Phys Med Biol, 47, 615, 10.1088/0031-9155/47/4/305 Hagemann, 2020, Advances in precision oncology: targeted thorium-227 conjugates as a new modality in targeted alpha therapy, Cancer Biother Radiopharm, 35, 497 Bailey, 2019, Biodistribution studies of chelated Ce-134/La-134 as positron-emitting analogues of alpha-emitting therapy radionuclides [abstract], J Nucl Med, 60, 130 Falzone, 2017, Absorbed dose evaluation of Auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values, Phys Med Biol, 62, 2239, 10.1088/1361-6560/aa5aa4